AIMS: Heart failure is a common antecedent to atrial fibrillation; both heart failure and atrial fibrillation are associated with increased myocardial oxidative stress. Chronic canine heart failure reduces atrial action potential duration and atrial refractoriness. We hypothesized that inducible nitric oxide synthase 2 (NOS2) contributes to atrial oxidative stress and electrophysiologic alterations. METHODS AND RESULTS: A 16-week canine tachypacing model of heart failure was used (n= 21). At 10 weeks, dogs were randomized to either placebo (n = 12) or active treatment (n = 9) with NOS cofactor, tetrahydrobiopterin (BH(4), 50 mg), and NOS substrate (L-arginine, 3 g) twice daily for 6 weeks. A group of matched controls (n = 7) was used for comparison. Heart failure increased atrial NOS2 and reduced atrial BH(4), while L-arginine was unchanged. Treatment reduced inducible atrial fibrillation and normalized the heart failure-induced shortening of the left atrial myocyte action potential duration. Treatment increased atrial [BH(4)] while [L-arginine] was unchanged. Treatment did not improve left ventricular function or dimensions. Heart failure-induced reductions in atrial [BH(4)] resulted in NOS uncoupling, as measured by NO and superoxide anion (O(2)(·-)) production, while BH(4) and L-arginine treatment normalized NO and O(2)(·-). Heart failure resulted in left atrial oxidative stress, which was attenuated by BH(4) and L-arginine treatment. CONCLUSION: Chronic non-ischaemic heart failure results in atrial oxidative stress and electrophysiologic abnormalities by depletion of BH(4) and uncoupling of NOS2. Modulation of NOS2 activity by repletion of BH(4) may be a safe and effective approach to reduce the frequency of atrial arrhythmias during heart failure.
AIMS: Heart failure is a common antecedent to atrial fibrillation; both heart failure and atrial fibrillation are associated with increased myocardial oxidative stress. Chronic canineheart failure reduces atrial action potential duration and atrial refractoriness. We hypothesized that inducible nitric oxide synthase 2 (NOS2) contributes to atrial oxidative stress and electrophysiologic alterations. METHODS AND RESULTS: A 16-week canine tachypacing model of heart failure was used (n= 21). At 10 weeks, dogs were randomized to either placebo (n = 12) or active treatment (n = 9) with NOS cofactor, tetrahydrobiopterin (BH(4), 50 mg), and NOS substrate (L-arginine, 3 g) twice daily for 6 weeks. A group of matched controls (n = 7) was used for comparison. Heart failure increased atrial NOS2 and reduced atrial BH(4), while L-arginine was unchanged. Treatment reduced inducible atrial fibrillation and normalized the heart failure-induced shortening of the left atrial myocyte action potential duration. Treatment increased atrial [BH(4)] while [L-arginine] was unchanged. Treatment did not improve left ventricular function or dimensions. Heart failure-induced reductions in atrial [BH(4)] resulted in NOS uncoupling, as measured by NO and superoxide anion (O(2)(·-)) production, while BH(4) and L-arginine treatment normalized NO and O(2)(·-). Heart failure resulted in left atrial oxidative stress, which was attenuated by BH(4) and L-arginine treatment. CONCLUSION: Chronic non-ischaemic heart failure results in atrial oxidative stress and electrophysiologic abnormalities by depletion of BH(4) and uncoupling of NOS2. Modulation of NOS2 activity by repletion of BH(4) may be a safe and effective approach to reduce the frequency of atrial arrhythmias during heart failure.
Authors: A Blum; L Hathaway; R Mincemoyer; W H Schenke; M Kirby; G Csako; M A Waclawiw; J A Panza; R O Cannon Journal: Circulation Date: 2000-05-09 Impact factor: 29.690
Authors: C A Carnes; M K Chung; T Nakayama; H Nakayama; R S Baliga; S Piao; A Kanderian; S Pavia; R L Hamlin; P M McCarthy; J A Bauer; D R Van Wagoner Journal: Circ Res Date: 2001-09-14 Impact factor: 17.367
Authors: Jared W Magnani; Victor M Johnson; Lisa M Sullivan; Eiran Z Gorodeski; Renate B Schnabel; Steven A Lubitz; Daniel Levy; Patrick T Ellinor; Emelia J Benjamin Journal: Am J Cardiol Date: 2011-01-20 Impact factor: 2.778
Authors: Ulf Landmesser; Sergey Dikalov; S Russ Price; Louise McCann; Tohru Fukai; Steven M Holland; William E Mitch; David G Harrison Journal: J Clin Invest Date: 2003-04 Impact factor: 14.808
Authors: Hjalti Gudmundsson; Jerry Curran; Farshid Kashef; Jedidiah S Snyder; Sakima A Smith; Pedro Vargas-Pinto; Ingrid M Bonilla; Robert M Weiss; Mark E Anderson; Philip Binkley; Robert B Felder; Cynthia A Carnes; Hamid Band; Thomas J Hund; Peter J Mohler Journal: J Mol Cell Cardiol Date: 2012-03-03 Impact factor: 5.000
Authors: Roberto Biondi; Giuseppe Ambrosio; Francesco De Pascali; Isabella Tritto; Enrico Capodicasa; Lawrence J Druhan; Craig Hemann; Jay L Zweier Journal: Arch Biochem Biophys Date: 2012-01-20 Impact factor: 4.013
Authors: Nathan E K Procter; Jocasta Ball; Doan T M Ngo; Yuliy Y Chirkov; Jeffrey S Isenberg; Elaine M Hylek; Simon Stewart; John D Horowitz Journal: Herz Date: 2015-07-02 Impact factor: 1.443
Authors: Renate B Schnabel; Renke Maas; Na Wang; Xiaoyan Yin; Martin G Larson; Daniel Levy; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Dorothee Atzler; Rainer H Böger; Edzard Schwedhelm; Ramachandran S Vasan; Emelia J Benjamin Journal: Am Heart J Date: 2016-03-17 Impact factor: 4.749